Combustible cigarettes are losing market share to three alternatives simultaneously. Heated tobacco products, e-cigarettes, and nicotine pouches each deliver nicotine through a completely different mechanism. For manufacturers and ingredient suppliers, this fragmentation is the defining reality of the modern nicotine industry.
One supplier portfolio. Three different product specs. Three different regulatory regimes.
The numbers tell the story. Philip Morris International reported that smoke-free products accounted for 41.5% of its $40.6 billion in net revenues in 2025, with smoke-free shipment volumes up 12.8% and ZYN shipments reaching 794 million cans (PMI 2025 fourth-quarter and full-year results). Every large manufacturer is reporting a version of the same shift, in different proportions. The money is moving, and the supply chain has to move with it.
Heated Tobacco: Combustion's Nearest Neighbor
Heated tobacco products (HTPs) use specially designed tobacco sticks heated to a few hundred degrees C, typically quoted in the 250-350 range. That is well below the temperatures at the burning tip of a cigarette, where combustion runs several hundred degrees hotter. The result: nicotine and flavor release without tar and many of the harmful compounds that combustion generates.
The major players:
- IQOS (Philip Morris International). The category leader. Blade-based heating system with HEETS/TEREA tobacco sticks. PMI reported more than 43 million estimated adult users across its whole smoke-free portfolio at the end of 2025.
- glo (BAT). Induction heating with Neostiks. Strong presence in Japan, Korea, and parts of Europe.
- Ploom (JTI). Redesigned induction heating platform gaining traction in Japan and Italy.
- lil (KT&G). South Korea's domestic champion, now expanding internationally.
Japan remains the largest HTP market by a wide margin. The Japanese government's classification of HTPs under existing tobacco tax frameworks (rather than imposing new regulatory categories) gave the format a head start there that other markets have not replicated.
Where nicotine suppliers fit: HTPs primarily use processed tobacco, not extracted nicotine. But that is changing. Next-generation HTP designs increasingly use nicotine-enriched substrates and reconstituted tobacco sheets with added nicotine to hit target delivery levels. PMI's LEVIA product, which uses a tobacco-free nicotine substrate, signals where this category is heading. When HTPs move beyond tobacco leaf, they need pharmaceutical-grade nicotine alkaloid or high-purity freebase nicotine as a raw material. This is a growing segment for extracted nicotine suppliers and one that demands tight purity documentation.
The technical challenge is consistency. Reconstituted sheets need uniform nicotine distribution to deliver predictable pharmacokinetics. Suppliers serving this segment need to provide detailed certificates of analysis, batch-to-batch consistency data, and often custom concentration specifications.
Vaping: The Extracted Nicotine Market
Vaping devices heat e-liquid (nicotine dissolved in VG/PG carriers with flavorings) into an inhalable aerosol. No tobacco leaf involved. The nicotine is extracted, purified, and dissolved. This is the segment where extracted nicotine suppliers have historically done the most volume.
Three hardware segments, three trajectories:
- Open systems (refillable tanks and mods). Declining in most regulated markets due to tightening restrictions. Still significant in parts of Asia and among enthusiast communities.
- Closed systems/pods (JUUL, VUSE, IQOS VEEV, etc.). The dominant format in regulated markets. Manufacturers control the full supply chain from ingredient to finished good.
- Disposables. The fastest-growing format by unit sales for several years, and now the one facing the sharpest regulatory reversal. Belgium banned single-use vapes from January 2025 and France followed in February 2025. The UK ban took effect on 1 June 2025. There is still no EU-wide ban, and the European Commission's revision of the Tobacco Products Directive remained at the pre-proposal stage as of August 2026. Australia took a different route entirely: under the 2024 vaping reforms, disposable and non-therapeutic vapes are prohibited outright and nicotine vapes are supplied only through pharmacies, available to adults without a prescription at 20 mg/mL or below (TGA vaping hub).
The disposable crackdown is reshaping procurement. As markets close to disposables, volume shifts to closed pod systems and (in some regions) back to open systems. For nicotine ingredient suppliers, this changes order patterns. Disposable manufacturers tend to place large, infrequent bulk orders. Pod system manufacturers run more consistent, specification-driven procurement cycles with stricter quality requirements.
Nicotine requirements are specific. E-liquid manufacturing needs high-purity extracted nicotine in precise forms:
- Freebase nicotine at USP/EP grade (99.5%+ purity) for traditional e-liquids. Understanding what USP/EP grade actually means matters here, because not every supplier claiming pharmacopoeial grade can back it up with proper documentation.
- Nicotine salts for pod systems and higher-concentration formulations. Salt-based e-liquids dominate the closed-system market because they deliver higher nicotine concentrations with less throat irritation. NicAlliance supplies two documented chemistries, nicotine benzoate and nicotine salicylate, each with its own CAS number, specification, safety data sheet and batch certificate.
- Pre-mixed nicotine dilutions in VG/PG carriers, blended to the concentration and carrier ratio you specify rather than sold as fixed grades. The choice between VG and PG as a carrier has real consequences for viscosity, flavor interaction, and device compatibility.
The carrier choice alone changes your production process, flavor profile, and target device compatibility. VG-based dilutions produce thicker vapor and smoother throat hit. PG-based dilutions carry flavor more effectively and work better in lower-power devices. Most manufacturers need both on hand, and some need custom ratios.
One underappreciated trend: nicotine concentration standardization. The EU TPD caps e-liquid at 20 mg/mL. The UK follows the same limit. But other markets allow higher concentrations (50 mg/mL is common in the US and parts of Asia). Manufacturers serving multiple geographies need ingredient suppliers who can deliver nicotine at different concentrations and in different salt forms, all with the regulatory documentation appropriate to each destination market.
Nicotine Pouches: The Fastest Segment
No heating element. No liquid. No tobacco leaf. Just a small white pouch between the lip and gum delivering nicotine through oral mucosal absorption.
The global pouch market is the fastest-growing part of the nicotine business, though category-level forecasts vary so widely between analyst houses that company disclosures are the sounder guide. Swedish Match (now owned by PMI) pioneered the modern format with ZYN, which shipped 794 million cans globally in 2025 (PMI 2025 fourth-quarter and full-year results). Competitors have piled in. BAT's VELO, Turning Point Brands' FRE, Kretek International's NIIN, and dozens of smaller players are all fighting for shelf space.
Consumer adoption is driven by a simple value proposition: discreet, smoke-free, spit-free nicotine that can be used anywhere. Regulators have generally been more receptive to a product with no combustion, no inhalation, and no tobacco leaf. The US FDA granted modified risk tobacco product authorization to General Snus in 2019, authorized the first nicotine pouches for sale in January 2025, and in June 2026 allowed a specific modified risk claim on 20 ZYN products. The regulatory environment for tobacco-free pouches remains more favorable than for vaping in most jurisdictions.
Nicotine requirements are different again:
- Nicotine bitartrate dihydrate. The dominant form for pouches. Solid at room temperature, water-soluble, and stable in storage. It allows precise milligram dosing in manufacturing, which is critical when your product label says "6 mg" and regulators will test to verify. The technical advantages of bitartrate over other forms for oral products are well documented.
- Nicotine polacrilex. An ion-exchange resin complex used in controlled-release applications. This is the same form used in nicotine gum (Nicorette and generics). Pouch manufacturers targeting pharmaceutical or quasi-pharmaceutical positioning use polacrilex for its established regulatory history.
- Freebase nicotine. Used in some higher-strength formulations, though less common in pouches due to stability and dosing precision challenges.
The manufacturing process for nicotine pouches is more similar to food or pharmaceutical production than to tobacco manufacturing. Pouch producers need ingredient suppliers who understand GMP environments, provide certificates of analysis that meet pharmaceutical standards, and can deliver consistent batch quality. A guide on choosing your nicotine supplier is worth reviewing if you are evaluating options for pouch production.
Three Formats, One Supply Chain Problem
Here is what the fragmentation means in practice:
Product portfolio breadth
A decade ago, most extracted nicotine demand was for e-liquid. Today, a supplier needs to serve e-liquid manufacturers, pouch producers, pharmaceutical NRT companies, and increasingly HTP customers. Each one has different product specs. Different concentration requirements. Different documentation standards.
NicAlliance is one of the suppliers that has built a portfolio spanning all these segments, from pure nicotine and salts to bitartrate and polacrilex. But portfolio breadth alone is not enough. The real question is whether a supplier can deliver each product with the documentation and quality assurance specific to its end use.
Quality standards are converging upward
Even non-pharmaceutical products now routinely require pharmacopoeial-grade nicotine. This is not manufacturers being cautious. It is regulators and retail buyers raising the floor. The gap between "pharmaceutical grade" and "everything else" is closing because everything else is being pulled up to pharmaceutical standards.
The FDA's PMTA process has been a major driver in the US. Even though PMTAs apply to finished products, the FDA expects detailed characterization of every ingredient, including nicotine source, purity, impurity profiles, and supplier quality systems. Manufacturers who sourced nicotine from unverified suppliers have found their PMTA submissions rejected or delayed. The risks of working with unverified suppliers are not hypothetical; they show up as regulatory delays, product recalls, and lost market access.
In Europe, TPD compliance requires emissions testing, ingredient notification, and toxicological data. The nicotine ingredient supplier's documentation feeds directly into those submissions. ISO, HACCP, and GMP certifications are table stakes, not differentiators.
Regulatory complexity multiplies
HTPs face tobacco product regulation in most markets. Vapes face TPD in Europe, PMTA in the US, and varying frameworks elsewhere. Pouches face novel food regulations in some markets and tobacco-adjacent regulation in others. A country-by-country regulatory guide is practically required reading for anyone selling into multiple geographies.
Your nicotine supplier needs to understand these distinctions because the documentation they provide feeds directly into your regulatory filings. A certificate of analysis formatted for EU TPD notification looks different from one supporting a US PMTA. A supplier who provides a single generic COA for all markets is creating work for your regulatory team (or worse, creating risk).
Traceability has become a competitive requirement, not just a nice-to-have. Regulators increasingly want to see chain of custody from tobacco field through extraction, purification, and delivery. STC certification and similar programs exist specifically to provide this kind of verified traceability.
New forms, new opportunity
The evolution is not over. Novel nicotine salts, encapsulated nicotine, slow-release formulations, and nicotine-enriched substrates are all in active development. Manufacturers with supplier relationships that include R&D collaboration will move faster than those treating nicotine as a commodity purchase.
Oral nicotine products beyond pouches are emerging. Nicotine toothpicks, lozenges, gummies, and dissolving strips are all in various stages of development or market launch. Each format has its own release kinetics, stability requirements, and regulatory pathway. The common thread is that all of them need precisely characterized, pharmaceutical-quality nicotine as a starting ingredient.
Ethical sourcing and ESG considerations are also becoming procurement criteria, particularly for publicly traded manufacturers and those selling into European markets. Supply chain transparency is no longer optional for companies that answer to institutional investors or face EU due diligence regulations.
What This Means for Procurement
Few manufacturers today source nicotine for a single product format in a single market. The trend is toward multi-format portfolios sold across multiple regulatory jurisdictions.
That reality puts pressure on the supplier relationship. You need a supplier who can deliver freebase nicotine for your e-liquid line, bitartrate for your pouch line, and polacrilex for your NRT products, all at pharmacopoeial grade with documentation tailored to each destination market.
The alternative is managing three or four supplier relationships, each with its own qualification process, audit schedule, and supply risk profile. Some manufacturers do this deliberately for supply security. For many others, it is an unintentional result of outgrowing a supplier who only serves one segment.
The nicotine delivery landscape will keep fragmenting. The manufacturers who navigate this successfully will be those with supply chain foundations flexible enough to support whatever comes next.
Frequently Asked Questions
How do nicotine purity requirements differ between heated tobacco, vaping, and pouch products?
All three segments are converging toward pharmacopoeial-grade nicotine (USP/EP, 99.5%+ purity), but the specific documentation and form requirements differ. Vaping products typically need liquid freebase nicotine or nicotine salts dissolved in VG/PG carriers. Pouch products need solid forms like nicotine bitartrate dihydrate or nicotine polacrilex for precise milligram dosing. Heated tobacco products using nicotine-enriched substrates need high-purity nicotine with detailed characterization of impurity profiles. Regardless of format, regulators increasingly expect pharmaceutical-level quality documentation from ingredient suppliers.
Can a single nicotine supplier serve manufacturers across all three delivery formats?
Yes, but only if the supplier maintains a broad product portfolio and the quality infrastructure to support each format's requirements. This means offering freebase nicotine, multiple salt forms, bitartrate, polacrilex, and pre-mixed dilutions, all with appropriate certifications and documentation. Manufacturers should evaluate whether a potential supplier can provide format-specific certificates of analysis, support regulatory filings in target markets, and maintain consistent batch quality across product lines. Working with a single qualified supplier simplifies auditing and reduces qualification overhead.
What regulatory documentation should I expect from a nicotine ingredient supplier?
At minimum, expect certificates of analysis for each batch showing purity, impurity profiles, residual solvents, and heavy metals. Beyond that, suppliers should provide documentation supporting your specific regulatory submissions. For US PMTA filings, that includes detailed ingredient characterization and manufacturing process descriptions. For EU TPD compliance, it includes data supporting emissions testing and ingredient notification. Traceability documentation from field to shipment, GMP compliance records, and ISO certification are standard expectations. Suppliers who provide only generic documentation are creating regulatory risk for their customers.
How is the shift away from disposable vapes affecting nicotine ingredient demand?
The regulatory crackdown on disposable vapes in several EU member states, the UK, Australia, and other markets is redirecting demand rather than eliminating it. Volume is shifting toward closed pod systems (which have stricter and more consistent ingredient specifications) and toward non-inhalable formats like nicotine pouches. For ingredient suppliers, this means more demand for nicotine salts in precise formulations, increased demand for solid nicotine forms like bitartrate, and higher documentation requirements overall. The net effect is a market that demands more product variety, tighter quality control, and better regulatory support from its nicotine suppliers.